McIlrath & Eck’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $84.7K | Hold |
1,057
| – | – | 0.01% | 411 |
|
|
2025
Q4 | $90.1K | Buy |
1,057
+135
| +15% | +$11.1K | 0.01% | 261 |
|
|
2025
Q3 | $71.7K | Sell |
922
-160
| -15% | -$12.5K | 0.01% | 249 |
|
|
2025
Q2 | $84.7K | Hold |
1,082
| – | – | 0.01% | 224 |
|
|
2025
Q1 | $78.4K | Hold |
1,082
| – | – | 0.01% | 232 |
|
|
2024
Q4 | $80.1K | Sell |
1,082
-138
| -11% | -$9.66K | 0.01% | 220 |
|
|
2024
Q3 | $80.5K | Sell |
1,220
-105
| -8% | -$7.63K | 0.01% | 218 |
|
|
2024
Q2 | $122K | Hold |
1,325
| – | – | 0.02% | 152 |
|
|
2024
Q1 | $127K | Sell |
1,325
-54
| -4% | -$4.54K | 0.02% | 151 |
|
|
2023
Q4 | $105K | Hold |
1,379
| – | – | 0.02% | 161 |
|
|
2023
Q3 | $95.5K | Sell |
1,379
-15
| -1% | -$1.21K | 0.02% | 173 |
|
|
2023
Q2 | $131K | Sell |
1,394
-90
| -6% | -$7.82K | 0.03% | 136 |
|
|
2023
Q1 | $123K | Sell |
1,484
-50
| -3% | -$3.93K | 0.03% | 139 |
|
|
2022
Q4 | $114K | Hold |
1,534
| – | – | 0.03% | 137 |
|
|
2022
Q3 | $127K | Hold |
1,534
| – | – | 0.03% | 120 |
|
|
2022
Q2 | $146K | Sell |
1,534
-50
| -3% | -$5.18K | 0.05% | 104 |
|
|
2022
Q1 | $186K | Hold |
1,584
| – | – | 0.05% | 85 |
|
|
2021
Q4 | $205K | Buy |
1,584
+106
| +7% | +$12.4K | 0.06% | 84 |
|
|
2021
Q3 | $167K | Hold |
1,478
| – | – | 0.05% | 86 |
|
|
2021
Q2 | $153K | Hold |
1,478
| – | – | 0.05% | 99 |
|
|
2021
Q1 | $124K | Buy |
1,478
+221
| +18% | +$18.7K | 0.04% | 101 |
|
|
2020
Q4 | $115K | Buy |
1,257
+81
| +7% | +$6.72K | 0.04% | 87 |
|
|
2020
Q3 | $94K | Buy |
1,176
+90
| +8% | +$7.02K | 0.04% | 90 |
|
|
2020
Q2 | $75K | Sell |
1,086
-234
| -18% | -$16.6K | 0.03% | 94 |
|
|
2020
Q1 | $83K | Hold |
1,320
| – | – | 0.05% | 77 |
|
|
2019
Q4 | $103K | Sell |
1,320
-300
| -19% | -$23.4K | 0.05% | 76 |
|
|
2019
Q3 | $119K | Sell |
1,620
-75
| -4% | -$5.27K | 0.06% | 60 |
|
|
2019
Q2 | $108K | Hold |
1,695
| – | – | 0.06% | 68 |
|
|
2019
Q1 | $108K | Sell |
1,695
-225
| -12% | -$12.8K | 0.06% | 68 |
|
|
2018
Q4 | $98K | Sell |
1,920
-120
| -6% | -$6.07K | 0.06% | 65 |
|
|
2018
Q3 | $118K | Hold |
2,040
| – | – | 0.07% | 69 |
|
|
2018
Q2 | $99K | Sell |
2,040
-1,986
| -49% | -$92.7K | 0.06% | 72 |
|
|
2018
Q1 | $187K | Buy |
+4,026
| New | +$175K | 0.11% | 53 |
|
Other funds holding EW
VCM
VPM
McIlrath & Eck's EW Position: Q1 2026 in Review
McIlrath & Eck held its Edwards Lifesciences (EW) position steady in Q1 2026 at 1,057 shares worth $84.7K. The position accounts for 0.01% of the portfolio, ranked #411.
McIlrath & Eck first reported a position in EW in Q1 2018 and has held it in 33 quarters since. The position peaked at $205K in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- McIlrath & Eck held 1,057 shares of Edwards Lifesciences worth $84.7K as of Q1 2026.
- McIlrath & Eck left its Edwards Lifesciences share count unchanged in Q1 2026.
- Edwards Lifesciences made up 0.01% of McIlrath & Eck's portfolio in Q1 2026, its #411 holding.
- McIlrath & Eck first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 33 quarters since.
- McIlrath & Eck's Edwards Lifesciences position peaked at $205K in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.